SECURITY AND TOLERANCE OF UNCARIA TOMENTOSA (WILLD) DC IN HEALTHY VOLUNTEERS

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

REPEC

Registry ID

PER-037-08

Enrollment

Registered

2008-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z00 General examination and investigation of persons without complaint and reported diagnosis General examination and investigation of persons without complaint and reported diagnosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Volunteers considered healthy by clinical and laboratory evaluation. • That you agree to be considered within the study. • Women who are not gestating or giving breastfeeding • Sign your consent to participate.

Exclusion criteria

Exclusion criteria: • Volunteers who present a disease or symptomatology. • Volunteers who are ingesting some type of drug or vitamin supplement. • Patients who do not wish to sign the informed consent

Design outcomes

Primary

Measure	Time frame
The verbal manifestations of the volunteer will be considered on any symptom, the vital signs, the biological functions as well as the anthropometric measurement will be monitored. NAME OF THE RESULT: Variations in clinical evaluation PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study	—

Secondary

Measure	Time frame
The verbal manifestations of the volunteer will be considered on any symptom, the vital signs, the biological functions as well as the anthropometric measurement will be monitored. NAME OF THE RESULT: Variations in clinical evaluation PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;Hematological Profile: Hemoglobin, CBC. platelet count. Renal profile: Creatinine, urea, urinary sediment, chemical urine test (uri-test method 9). Liver profile Immunological profile: CD4 and CD8 Other tests: Glucose, cholesterol, LDL, HDL and uric acid NAME OF THE RESULT: Variation in the levels of laboratory tests PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;Electrocardiogram during the study NAME OF THE RESULT: Variations in the eiectrocardiographic Registry. PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;An ophthalmological profile will be performed during the study NAME OF THE RESULT: Variations in the ophthalmological profile PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;An endoscopic study with biopsy will be conducted, which will be directed by the gastroenterologist. This sample will be taken at the beginning and at 90 days of treatment. The sample will be evaluated by the pathologist. NAME OF THE RESULT: Variations in endoscopic evaluation with biopsy PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study	—

Measure

Time frame

The verbal manifestations of the volunteer will be considered on any symptom, the vital signs, the biological functions as well as the anthropometric measurement will be monitored. NAME OF THE RESULT: Variations in clinical evaluation PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;Hematological Profile: Hemoglobin, CBC. platelet count. Renal profile: Creatinine, urea, urinary sediment, chemical urine test (uri-test method 9). Liver profile Immunological profile: CD4 and CD8 Other tests: Glucose, cholesterol, LDL, HDL and uric acid NAME OF THE RESULT: Variation in the levels of laboratory tests PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;Electrocardiogram during the study NAME OF THE RESULT: Variations in the eiectrocardiographic Registry. PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;An ophthalmological profile will be performed during the study NAME OF THE RESULT: Variations in the ophthalmological profile PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study;An endoscopic study with biopsy will be conducted, which will be directed by the gastroenterologist. This sample will be taken at the beginning and at 90 days of treatment. The sample will be evaluated by the pathologist. NAME OF THE RESULT: Variations in endoscopic evaluation with biopsy PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: During the study

—

Countries

Peru

Outcome results